HC Wainwright Reaffirms “Buy” Rating for Werewolf Therapeutics (NASDAQ:HOWL)

Werewolf Therapeutics (NASDAQ:HOWLGet Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $15.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 244.04% from the stock’s current price.

A number of other analysts also recently commented on HOWL. JMP Securities reissued a “market outperform” rating and set a $12.00 price objective on shares of Werewolf Therapeutics in a report on Monday, May 6th. Wedbush restated an “outperform” rating and set a $9.00 target price on shares of Werewolf Therapeutics in a research report on Monday, May 6th.

Get Our Latest Report on HOWL

Werewolf Therapeutics Stock Performance

Shares of NASDAQ:HOWL traded down $0.81 during midday trading on Monday, hitting $4.36. The stock had a trading volume of 145,514 shares, compared to its average volume of 221,917. The company has a market capitalization of $189.49 million, a PE ratio of -4.00 and a beta of 0.62. The stock has a 50 day moving average price of $5.62 and a two-hundred day moving average price of $5.06. The company has a current ratio of 6.71, a quick ratio of 6.71 and a debt-to-equity ratio of 0.24. Werewolf Therapeutics has a 1 year low of $1.57 and a 1 year high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWLGet Free Report) last released its quarterly earnings data on Friday, May 3rd. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The company had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $5.00 million. Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. As a group, equities analysts predict that Werewolf Therapeutics will post -1.52 earnings per share for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Several institutional investors have recently added to or reduced their stakes in HOWL. Financial Perspectives Inc increased its holdings in shares of Werewolf Therapeutics by 80.0% in the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after acquiring an additional 3,000 shares during the last quarter. Certuity LLC bought a new position in Werewolf Therapeutics during the 4th quarter worth $39,000. Lighthouse Investment Partners LLC bought a new position in Werewolf Therapeutics during the 4th quarter worth $87,000. Denali Advisors LLC bought a new position in Werewolf Therapeutics during the 1st quarter worth $172,000. Finally, Acadian Asset Management LLC grew its stake in Werewolf Therapeutics by 119.8% during the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock worth $1,119,000 after buying an additional 94,212 shares during the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

Featured Articles

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.